SLC5A2 and urinary bladder carcinoma: After including 97,024 T2DM patients without previous or active bladder cancer and with follow-up for 2.8 years, the combination therapy of SGLT-2 inhibitors and Pio was not found to be associated with newly diagnosed bladder cancer in this short-term research from CGRD.